Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices 16369 

complete the questionnaire with the 

instructions provided. 

The activity-based cost data provided 

by the 68 grantees will be used to 

evaluate the programs to ensure the 

most appropriate use of limited program 

resources. Performing an assessment of 

the resources expended on NBCCEDP 

will provide valuable information to the 

CDC and it partners for improving 

program efficiency within the various 

components of the NBCCEDP including 

screening, case management, outreach, 

and overall management. The detailed 

cost data will allow CDC to assess the 

costs of the various program 

components, identify factors that impact 

average cost, perform cost-effectiveness 

analysis and develop a resource 

allocation tool. The collection and 

analysis of the cost data will allow CDC 

to utilize a more systematic process to 

allocate program resources based on 

grantees’ past performance, level of 

efficiency, and future needs. 

Since information on screening and 

diagnosis volumes (the effectiveness 

measures) are already collected as part 

of the Minimum Data Elements (MDEs), 

the additional burden on grantees to 

provide the requested cost data will be 

modest. If future cost data collection 

efforts are undertaken, the response 

burden would be further reduced 

because the infrastructure established to 

capture the data is already in place. 

There are no costs to respondents 

except their time to participate in the 

survey. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Program Director ............................... Cost Assessment Tool ..................... 68 1 4 272 

Business Manager ............................ ........................................................... 68 1 4 272 

Data Manager ................................... ........................................................... 68 1 14 952 

Total ........................................... ........................................................... ........................ ........................ ........................ 1,496 

Dated: March 28, 2007. 

Joan F. Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–6275 Filed 4–3–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–07–06AY] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Joan Karr, CDC 

Acting Reports Clearance Officer, 1600 

Clifton Road, MS–D74, Atlanta, GA 

30333 or send an e-mail to 

omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Evaluation of the Spanish-Language 

Campaign ‘‘Good Morning Arthritis, 

Today you will not defeat us.’’—New—

National Center for Chronic Disease 

Prevention and Health Promotion 

(NCCDPHP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

Arthritis affects nearly 43 million 

Americans, or about one in every six 

people, and is the leading cause of 

disability among adults in the United 

States. Because of the broad public 

health impact of this disease, the 

Centers for Disease Control and 

Prevention (CDC) developed the 

National Arthritis Action Plan in 1998 

as a comprehensive approach to 

reducing the burden of arthritis in the 

United States. 

As part of its efforts to implement the 

National Arthritis Action Plan, CDC 

developed and tested a health 

communications campaign promoting 

physical activity among Caucasian and 

African-American adults with arthritis. 

In 2003–2004, CDC developed a similar 

campaign for Spanish-speaking people 

with arthritis. Hispanic populations 

have a slightly lower prevalence rate of 

self-reported, doctor-diagnosed arthritis, 

but Hispanics with arthritis report 

greater work limitations, and higher 

rates of severe pain than do Caucasian 

populations with arthritis. 

The Spanish-language campaign, 

Good Morning Arthritis, Today you will 

not defeat us, is designed to reach 

Spanish speaking adults with arthritis 

who are aged 45–64, who have high 

school education or less, and whose 

annual income is less than $35,000. The 

key message elements of the Spanish 

language health communications 

campaign are similar to its English 

counterpart, as are the campaign 

objectives and materials. The campaign 

objectives are to increase target 

audience members’ (1) Beliefs about 

physical activity as an arthritis 

management strategy (there are ‘‘things 

they can do’’ to make arthritis better, 

and physical activity is an important 

part of arthritis management); (2) 

Knowledge of the benefits of physical 

activity and appropriate physical 

activity for people with arthritis; (3) 

Confidence in their ability to be 

physically active, and (4) Trial of 

physical activity behaviors. Based on 

formative research, campaign materials 

refer to exercise instead of physical 

activity. Campaign materials include; 

print ads, 30- and 60-second radio ads 

and public service announcements, and 

desktop displays with brochures for 


jlentini on PROD1PC65 with NOTICES
16370 Federal Register / Vol. 72, No. 64 / Wednesday, April 4, 2007 / Notices 

pharmacies, doctors’ offices, and 

community centers. 

In the Fall of 2005, the Spanish 

language campaign was pilot tested by 

5 state health departments that receive 

funding from CDC for their arthritis 

programs. CDC will eventually 

disseminate these materials to all 36 

CDC-funded states. The 5 preliminary 

pilot tests focused on reach and 

exposure; a more thorough evaluation is 

necessary to assess impact of the 

campaign. This information will be used 

to guide the public health practice of the 

36 state arthritis programs and their 

partners. 

CDC will conduct an evaluation of the 

impact of the Spanish language health 

communications campaign on the 

exercise/physical activity-related 

attitudes, beliefs, and behaviors among 

the target audience of Spanish-speaking 

people with arthritis. There are no costs 

to the respondents other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Screening Survey ............................................................................................ 12,000 1 2/60 400 

Telephone Survey ............................................................................................ 2,500 1 15/60 625 

Total .......................................................................................................... ........................ ........................ ........................ 1,025 

Dated: March 28, 2007. 

Joan F. Karr, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–6276 Filed 4–3–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Technical 

Support for Birth Defects and 

Developmental Disabilities Prevention 

Education Efforts, Contract Solicitation 

Number (CSN) 2006–N–08835 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned SEP: 

Time and Date: 12 p.m.–3 p.m., April 

30, 2007 (Closed). 

Place: Teleconference, Centers for 

Disease Control and Prevention, 1600 

Clifton Road, NE., Atlanta, GA 30333. 

Status: The meeting will be closed to 

the public in accordance with 

provisions set forth in Section 

552b(c)(4) and (6), Title 5 U.S.C., and 

the Determination of the Director, 

Management Analysis and Services 

Office, CDC, pursuant to Public Law 92–

463. 

Matters to be Discussed: The meeting 

will include the review, discussion, and 

evaluation of applications received in 

response to CSN 2006–N–08835, 

‘‘Technical Support for Birth Defects 

and Developmental Disabilities 

Prevention Education Efforts.’’

For Further Information Contact: 

Christine Morrison, Ph.D., Scientific 

Review Administrator, Centers for 

Disease Control and Prevention, 1600 

Clifton Road NE., Mailstop D72, Atlanta, 

GA 30333, Telephone 404.639.3098. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both CDC 

and the Agency for Toxic Substances 

and Disease Registry. 

Dated: March 28, 2007. 

Elaine L. Baker, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. E7–6270 Filed 4–3–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Preparation for International 

Conference on Harmonisation 

Meetings in Brussels, Belgium; Public 

Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of meeting. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing a 

public meeting entitled ‘‘Preparation for 

ICH Meetings in Brussels, Belgium’’ to 

provide information and receive 

comments on the International 

Conference on Harmonisation (ICH) as 

well as the upcoming meetings in 

Brussels, Belgium. The topics to be 

discussed are the topics for discussion 

at the forthcoming ICH steering 

committee meeting. The purpose of the 

meeting is to solicit public input prior 

to the next steering committee and 

expert working groups meetings in 

Brussels, Belgium May 5–10, 2007, at 

which discussion of the topics 

underway and the future of ICH will 

continue. 

Date and Time: The meeting will be 

held on Friday April 6, 2007, from 3:30 

p.m. to 5 p.m. 

Location: The meeting will be held at 

5600 Fishers Lane, third floor, 

Conference Room G, Rockville, MD 

20857. For security reasons, all 

attendees are asked to arrive no later 

than 3:20 p.m., as you will be escorted 

from the front entrance of 5600 Fishers 

Lane to Conference Room G. 

Contact Person: Michelle Limoli, 

Office of the Commissioner (HFG–1), 

Food and Drug Administration, 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–0908, e-mail: 

michelle.limoli@fda.hhs.gov, FAX: 301–

827–0003. 

Registration and Requests for Oral 

Presentations: Send registration 

information (including name, title, firm 

name, address, telephone, and fax 

number), written material, and requests 

to make oral presentations, to the 

contact person by April 5, 2007. 

If you need special accommodations 

due to a disability, please contact 

Michelle Limoli as soon as possible. 

SUPPLEMENTARY INFORMATION: The ICH 

was established in 1990 as a joint 

regulatory/industry project to improve, 

through harmonization, the efficiency of 

the process for developing and 

registering new medicinal products in 

Europe, Japan, and the United States 

without compromising the regulatory 

obligations of safety and effectiveness. 

In recent years, many important 

initiatives have been undertaken by 

regulatory authorities and industry 


jlentini on PROD1PC65 with NOTICES